<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32981026</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2192-4449</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>CEN case reports</Title>
          <ISOAbbreviation>CEN Case Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Quetiapine-induced thrombotic microangiopathy in a patient on maintenance dialysis.</ArticleTitle>
        <Pagination>
          <StartPage>159</StartPage>
          <EndPage>164</EndPage>
          <MedlinePgn>159-164</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s13730-020-00536-z</ELocationID>
        <Abstract>
          <AbstractText>Quetiapine has been reported to cause immune-mediated thrombotic microangiopathy (TMA), although few cases have been reported thus far. A 71-year-old man with autosomal dominant polycystic kidney disease on maintenance dialysis was hospitalized with a hemorrhagic basal ganglia stroke, and was treated with 25 mg quetiapine for delirium from day 4 of admission. There was no worsening of consciousness, fever, diarrhea, or elevated blood pressure during the hospitalization. Gingival bleeding appeared on day 35, and the platelet count on day 38 was 0.5 × 10<sup>4</sup>/μL (13.2 × 10<sup>4</sup>/μL on day 16). The presence of 1% schistocytes, high LDH level, inability to measure haptoglobin, negative direct Coombs test, and normal prothrombin time and activated partial thromboplastin time indicated TMA. We considered an exclusionary diagnosis of drug-induced TMA, because of normal ADAMTS13 activity, no evidence of complement activation and the absence of Shiga toxin or symptoms of collagen disease or cancer. Quetiapine was the most likely causative factor; however, all drugs, including heparin, were discontinued or changed. Due to persistent microbleeding, platelet transfusions were performed several times. After only quetiapine was discontinued, the platelet count recovered smoothly to 3.1 and 7.2 × 10<sup>4</sup>/μL on days 45 and 72, respectively; LDH and fibrinogen levels normalized on day 47. All medications, except quetiapine, were restarted sequentially after day 47, without subsequent thrombocytopenia. Platelet activation predominantly by a drug-dependent antibody might be the etiology of quetiapine-induced TMA. Plasmapheresis may not be necessary for quetiapine, because of its unproven efficacy in drug-induced TMA.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Takahashi</LastName>
            <ForeName>Miki</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Suwa Central Hospital, 4300 Tamagawa, Chino-shi, Nagano-ken, 391-8503, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deguchi</LastName>
            <ForeName>Akihito</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Suwa Central Hospital, 4300 Tamagawa, Chino-shi, Nagano-ken, 391-8503, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nishihara</LastName>
            <ForeName>Hiromu</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Suwa Central Hospital, 4300 Tamagawa, Chino-shi, Nagano-ken, 391-8503, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Asou</LastName>
            <ForeName>Mea</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Suwa Central Hospital, 4300 Tamagawa, Chino-shi, Nagano-ken, 391-8503, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Asakawa</LastName>
            <ForeName>Tomohiko</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Suwa Central Hospital, 4300 Tamagawa, Chino-shi, Nagano-ken, 391-8503, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Araki</LastName>
            <ForeName>Makoto</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-0854-4064</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, Suwa Central Hospital, 4300 Tamagawa, Chino-shi, Nagano-ken, 391-8503, Japan. makoto.araki@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>09</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>CEN Case Rep</MedlineTA>
        <NlmUniqueID>101636244</NlmUniqueID>
        <ISSNLinking>2192-4449</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>2S3PL1B6UJ</RegistryNumber>
          <NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016891" MajorTopicYN="N">Polycystic Kidney, Autosomal Dominant</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006435" MajorTopicYN="N">Renal Dialysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057049" MajorTopicYN="N">Thrombotic Microangiopathies</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">ADAMTS13</Keyword>
        <Keyword MajorTopicYN="Y">Hemodialysis</Keyword>
        <Keyword MajorTopicYN="Y">Quetiapine</Keyword>
        <Keyword MajorTopicYN="Y">Thrombotic microangiopathy</Keyword>
      </KeywordList>
      <CoiStatement>All the authors have declared no competing interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>27</Day>
          <Hour>20</Hour>
          <Minute>38</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32981026</ArticleId>
        <ArticleId IdType="pmc">PMC8019441</ArticleId>
        <ArticleId IdType="doi">10.1007/s13730-020-00536-z</ArticleId>
        <ArticleId IdType="pii">10.1007/s13730-020-00536-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Huynh M, Chee K, Lau DH. Thrombotic thrombocytopenic purpura associated with quetiapine. Ann pharmacother. 2005;39(7–8):1346–1348. doi: 10.1345/aph.1G067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1345/aph.1G067</ArticleId>
            <ArticleId IdType="pubmed">15914516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Husnain M, Gondal F, Raina AI, Riaz IB, Anwer F. Quetiapine associated thrombotic thrombocytopenic purpura: a case report and literature review. Am J Ther. 2017;24(5):e615–e616. doi: 10.1097/MJT.0000000000000456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MJT.0000000000000456</ArticleId>
            <ArticleId IdType="pubmed">27340908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Go RS, Winters JL, Leung N, Murray DL, Willrich MA, Abraham RS, et al.  Thrombotic microangiopathy care pathway: a consensus statement for the mayo clinic complement alternative pathway-thrombotic microangiopathy (CAP-TMA) disease-oriented group. Mayo Clin Proc. 2016;91(9):1189–1211. doi: 10.1016/j.mayocp.2016.05.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mayocp.2016.05.015</ArticleId>
            <ArticleId IdType="pubmed">27497856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129(21):2836–2846. doi: 10.1182/blood-2016-10-709857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2016-10-709857</ArticleId>
            <ArticleId IdType="pubmed">28416507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azoulay E, Knoebl P, Garnacho-Montero J, Rusinova K, Galstian G, Eggimann P, et al.  Expert statements on the standard of care in critically ill adult patients with atypical hemolytic uremic syndrome. Chest. 2017;152(2):424–434. doi: 10.1016/j.chest.2017.03.055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chest.2017.03.055</ArticleId>
            <ArticleId IdType="pubmed">28442312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wada H, Matsumoto T, Suzuki K, Imai H, Katayama N, Iba T, et al.  Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thromb J. 2018;16:14. doi: 10.1186/s12959-018-0168-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12959-018-0168-2</ArticleId>
            <ArticleId IdType="pmc">PMC6040080</ArticleId>
            <ArticleId IdType="pubmed">30008620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakurai S, Kato H, Yoshida Y, Sugawara Y, Fujisawa M, Yasumoto A, et al.  Profiles of coagulation and fibrinolysis activation-associated molecular markers of atypical hemolytic uremic syndrome in the acute phase. J Atheroscler Thromb. 2020;27(4):353–362. doi: 10.5551/jat.49494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5551/jat.49494</ArticleId>
            <ArticleId IdType="pmc">PMC7192816</ArticleId>
            <ArticleId IdType="pubmed">31484852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park YA, Waldrum MR, Marques MB. Platelet count and prothrombin time help distinguish thrombotic thrombocytopenic purpura-hemolytic uremic syndrome from disseminated intravascular coagulation in adults. Am J Clin Pathol. 2010;133(3):460–465. doi: 10.1309/AJCPPNF63FLIORCI.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1309/AJCPPNF63FLIORCI</ArticleId>
            <ArticleId IdType="pubmed">20154285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005;3(7):1432–1436. doi: 10.1111/j.1538-7836.2005.01436.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1538-7836.2005.01436.x</ArticleId>
            <ArticleId IdType="pubmed">15978100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reese JA, Bougie DW, Curtis BR, Terrell DR, Vesely SK, Aster RH, et al.  Drug-induced thrombotic microangiopathy: experience of the oklahoma registry and the bloodcenter of wisconsin. Am J Hematol. 2015;90(5):406–410. doi: 10.1002/ajh.23960.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.23960</ArticleId>
            <ArticleId IdType="pmc">PMC4409501</ArticleId>
            <ArticleId IdType="pubmed">25639727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood. 2015;125(4):616–618. doi: 10.1182/blood-2014-11-611335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2014-11-611335</ArticleId>
            <ArticleId IdType="pmc">PMC4304106</ArticleId>
            <ArticleId IdType="pubmed">25414441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu J, Bougie DW, Aster RH, Springer TA. Structural basis for quinine-dependent antibody binding to platelet integrin alphaIIbbeta3. Blood. 2015;126(18):2138–2145. doi: 10.1182/blood-2015-04-639351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2015-04-639351</ArticleId>
            <ArticleId IdType="pmc">PMC4626254</ArticleId>
            <ArticleId IdType="pubmed">26282540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang Y, McCombs JS, Park SH. A retrospective cohort study of acute kidney injury risk associated with antipsychotics. CNS Drugs. 2017;31(4):319–326. doi: 10.1007/s40263-017-0421-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40263-017-0421-4</ArticleId>
            <ArticleId IdType="pubmed">28290080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al.  Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the writing committee of the American society for apheresis: the eighth special issue. J Clin Apher. 2019;34(3):171–354. doi: 10.1002/jca.21705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jca.21705</ArticleId>
            <ArticleId IdType="pubmed">31180581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glynne P, Salama A, Chaudhry A, Swirsky D, Lightstone L. Quinine-induced immune thrombocytopenic purpura followed by hemolytic uremic syndrome. Am J Kidney Dis. 1999;33(1):133–137. doi: 10.1016/s0272-6386(99)70269-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0272-6386(99)70269-6</ArticleId>
            <ArticleId IdType="pubmed">9915279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goel R, Ness PM, Takemoto CM, Krishnamurti L, King KE, Tobian AA. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood. 2015;125(9):1470–1476. doi: 10.1182/blood-2014-10-605493.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2014-10-605493</ArticleId>
            <ArticleId IdType="pmc">PMC4342358</ArticleId>
            <ArticleId IdType="pubmed">25588677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wirtschafter E, VanBeek C, Linhares Y. Bone marrow transplant-associated thrombotic microangiopathy without peripheral blood schistocytes: a case report and review of the literature. Exp Hematol Oncol. 2018;7:14. doi: 10.1186/s40164-018-0106-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40164-018-0106-9</ArticleId>
            <ArticleId IdType="pmc">PMC6013965</ArticleId>
            <ArticleId IdType="pubmed">29977661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brus I, Lewis SM. The haptoglobin content of serum in haemolytic anaemia. Br J Haematol. 1959;5:348–355. doi: 10.1111/j.1365-2141.1959.tb04045.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2141.1959.tb04045.x</ArticleId>
            <ArticleId IdType="pubmed">13805399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwaan HC. Clinicopathologic features of thrombotic thrombocytopenic purpura. Semin Hematol. 1987;24(2):71–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3299721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levandovsky M, Harvey D, Lara P, Wun T. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients. J Hematol Oncol. 2008;1:23. doi: 10.1186/1756-8722-1-23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1756-8722-1-23</ArticleId>
            <ArticleId IdType="pmc">PMC2613392</ArticleId>
            <ArticleId IdType="pubmed">19046460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Remuzzi G, Galbusera M, Salvadori M, Rizzoni G, Paris S, Ruggenenti P. Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma. Kidney Int. 1996;49(1):282–286. doi: 10.1038/ki.1996.40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ki.1996.40</ArticleId>
            <ArticleId IdType="pubmed">8770981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feldman M, Bruno T, Chong YC, Borstad G, Wild C, Lopez JD, et al.  Bilateral nephrectomy for treatment resistant systemic lupus erythematosis and thrombotic thrombocytopenic purpura: a case report. Am J Hematol. 2007;82(6):496–497. doi: 10.1002/ajh.20842.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.20842</ArticleId>
            <ArticleId IdType="pubmed">17154378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perkins RM, Reynolds JC, Ahuja TS, Reid T, Agodoa LY, Bohen EM, et al.  Thrombotic microangiopathy in United States long-term dialysis patients. Nephrol Dial Transplant. 2006;21(1):191–196. doi: 10.1093/ndt/gfi153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ndt/gfi153</ArticleId>
            <ArticleId IdType="pubmed">16204286</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
